Varian gains more worldwide sites for RapidArc system

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 5
Volume 18
Issue 5

Varian gains more worldwide sites for RapidArc system

Varian Medical Systems has placed its RapidArc Radiotherapy unit at the following institutions:
• Bern University Hospital in Bern, Switzerland
• Chang Gung Memorial Hospital in Linkou, Taiwan
• Gottingen University Hospital in Gottingen, Germany
• Innovative Cancer Institute in S. Miami, Fla.
• Lehigh Valley Health Network in Allentown and Bethlehem, Penn.
• New Mexico Cancer Center in Albuquerque
• Northwoods Cancer Center in Woodlands, Tex.
• Pamela Youde Nethersole Eastern Hospital in Hong Kong
• Sudharz Krankenhaus in Nordhausen, Germany
• Trinitas Comprehensive Cancer Center in Elizabeth, N.J.
• Zurich University Hospital

Articles in this issue
Drug with tumor-specific target fells cancerous B cells while sparing healthy ones in NHL
Expanded Medicare coverage of PET draws kudos from oncology community
Who's News
Push for comparative effectiveness research
Should lymphadenectomy be the standard of care in melanoma metastasis to the sentinel lymph nodes?
Lack of persuasive data continues to plague PSA testing
Aggressive colon cancer treatment: A matter of tolerability vs necessity
Less toxic protocol proves efficacious in chronic lymphocytic leukemia pts
ASCO draws road map to navigate economic, racial disparities in ca care
Clinical trials flourish in international setting
Global lung ca staging lexicon undergoes major overhaul
Decision-analytic model aids cervical cancer treatment
Elekta pledges $1 million to support RT research
Varian gains more worldwide sites for RapidArc system
Focus on Lung Cancer
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content
The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

FDA Updates Fludarabine Phosphate Labeling in Chronic Lymphocytic Leukemia

Russ Conroy
November 21st 2024
Article

The updated labeling also includes new information on the recommended dosage of fludarabine phosphate when given with cyclophosphamide and rituximab.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

Multiple Myeloma Experts Face Off on Sequencing Therapy Options

ONCOLOGY Staff
November 21st 2024
Article

Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

EU Approval Recommended for Repotrectinib in ROS1+ NSCLC, NTRK+ Solid Tumors

Roman Fabbricatore
November 20th 2024
Article

Results from the TRIDENT-1 and CARE trials, which showcased durable activity and robust responses with repotrectinib, supported the recommendation.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.

Subcutaneous Pembrolizumab/Chemo Meets Pharmacokinetic Endpoints in NSCLC

Tim Cortese
November 20th 2024
Article

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.